Lipocine Inc. (NASDAQ:LPCN – Get Rating) – Cantor Fitzgerald issued their FY2023 earnings estimates for Lipocine in a report issued on Monday, March 13th. Cantor Fitzgerald analyst J. Kim forecasts that the specialty pharmaceutical company will earn ($0.12) per share for the year.
Separately, StockNews.com assumed coverage on shares of Lipocine in a research note on Sunday, March 12th. They set a “buy” rating on the stock.
Lipocine Stock Performance
Lipocine (NASDAQ:LPCN – Get Rating) last issued its quarterly earnings results on Friday, March 10th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter.
Institutional Trading of Lipocine
Large investors have recently made changes to their positions in the company. XTX Topco Ltd purchased a new stake in shares of Lipocine during the first quarter worth approximately $54,000. Wealthspan Partners LLC purchased a new stake in shares of Lipocine during the fourth quarter worth approximately $29,000. Renaissance Technologies LLC increased its stake in shares of Lipocine by 474.5% during the second quarter. Renaissance Technologies LLC now owns 81,006 shares of the specialty pharmaceutical company’s stock worth $65,000 after buying an additional 66,906 shares during the period. Bailard Inc. purchased a new position in Lipocine in the fourth quarter valued at approximately $32,000. Finally, Goldman Sachs Group Inc. increased its stake in Lipocine by 524.6% in the first quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 74,428 shares during the last quarter. 12.18% of the stock is currently owned by hedge funds and other institutional investors.
Lipocine, Inc is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders.
- Get a free copy of the StockNews.com research report on Lipocine (LPCN)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.